Long-term open-label extension study of tolvaptan in ADPKD

Phase 3, open-label trial of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by Covance. Primary endpoints: Percent change from original trial baseline in total kidney volume at Month 24 of extension and Change in renal function at Month 24 of extension. Started Feb 2011; status: active, not recruiting.